Excited to share ChronicleBio’s first clinical trial partnership, with Prolong Pharmaceuticals, evaluating PP-007 (Sanguinate) for post-exertional malaise in ME/CFS.
Heterogeneous diseases need this approach.
Heterogeneous diseases need this approach.
Today we are announcing our first clinical trial. We're joining forces with Prolong to evaluate a potential treatment for post exertional malaise (PEM) in #MECFS.View quoted post on X
Sanguinate is an investigational intravenous therapy designed to deliver oxygen to deprived tissues, support blood flow, and reduce inflammation. The planned multi-site Phase 2a trial will evaluate the drug in at least 40 patients with first dosing expected mid-2027.
Most trials enroll patients based on symptoms alone, but recruitment for this study will leverage ChronicleBio's proprietary endotype intelligence platform to identify patients whose disease biology suggests they may be more likely to respond.
We are excited for our partnership with Prolong and grateful for the patient community that drives everything we do.
Read More: chroniclebio.com/news/chronicle…
